To receive the Femtech World newsletter, sign up here.
Entrepreneur
Could this start-up turn the tide on ovarian cancer?
Ovarian cancer causes more deaths than any other cancer of the female reproductive system
Nearly 225,000 women are diagnosed with ovarian cancer globally every year, but over 50 per cent of them will not survive. Could this biotech start-up have the solution?
March marks Ovarian Cancer Awareness Month – a chance to put ovarian cancer in the spotlight.
The disease causes more deaths than any other cancer of the female reproductive system and, according to the American Cancer Society, will kill in 2024 12,740 women in the US alone.
Despite this, awareness remains low. New data from Target Ovarian Cancer shows that, while progress has been made, things are not moving fast enough, with 40 per cent of UK women confusing cervical cancer and ovarian cancer.
“We don’t have enough awareness and advocacy around ovarian cancer to elevate the importance of the disease the way we do around breast cancer,” says Oriana Papin-Zoghbi, co-founder and CEO of the biotech start-up AOA Dx.
She believes this is directly linked to the low incidence of the disease – there are about 240,000 new cases of breast cancer in the US every year, compared to just under 20,000 of cases of ovarian cancer.
However, she says: “While we don’t see hundreds of thousands of cases, the percentage of women who die of ovarian cancer is significantly higher than almost any other gynaecological cancer.”
Ovarian cancer’s high fatality rate is largely attributed to a failure to recognise symptoms early on and a series of misconceptions around the disease, such as the idea that ovarian cancer is a “silent killer”.
Papin-Zoghbi agrees. Most of the things we hear about ovarian cancer, she says, are not actually true.
“Around 87 per cent of women with ovarian cancer experience symptoms early on, but they are misconstrued for different things.
“The vague abdominal symptoms that we hear about are commonly mistaken for conditions like endometriosis or irritable bowel syndrome because there is no diagnostic to differentiate them.”
Currently, the only way to confirm an ovarian cancer diagnosis is a tissue biopsy. Most women have a biopsy during an operation called laparotomy, where the surgeons make a large cut down the middle of the abdomen to take samples of tissue.
However, in some cases, doctors have to remove an ovary and have it tested for signs of cancer to confirm a diagnosis.
Papin-Zoghbi and her team at Boston-based AOA Dx are aiming to develop the first early-stage ovarian cancer liquid biopsy diagnostic test, which could significantly cut down fatalities and make the diagnosis process less invasive.
“The fact that 80 per cent of women are diagnosed with stage three and four ovarian cancer is unacceptable. Women need a much better chance,” she says.
“We are hoping that our solution will help elevate our understanding of ovarian cancer.”
The technology has shown over 90 per cent accuracy for detection of ovarian cancer and raises hopes for thousands of women globally. However, it will take time.
“There are certain that are not in our control,” says Papin-Zoghbi.
“It takes up every waking moment to build a company, but we have a strong team and we are very positive about the the path forward.
“We closed a US$17m financing round in October and we are currently focusing on building our lab, developing our product pipeline and conducting our clinical study to validate our technology. In the next couple of years, our aim is to focus on product development and clinical study data ahead of thinking about how we will bring the product to market.
“We’re optimistic – we know we can have a transformational impact on women’s health.”
The Women’s Health Innovation Summit (WHIS) has announced that submissions are open for the 2026 Innovation Showcase, giving early and growth-stage start-ups the chance to present their solutions to the most influential audience in women’s health.
Taking place October 13–15 at Encore Boston Harbor in Everett, Massachusetts, WHIS brings together more than 1,000 decision-makers from across the women’s health ecosystem — investors, payers, health systems, pharma leaders, and employers — all under one roof.
Selected companies will pitch live on stage to an audience with the funding, expertise, and connections to accelerate their growth.
Past participants have walked away with investor introductions, commercial partnerships, and clinical collaborations that moved from conversation to contract.
WHIS is where the women’s health ecosystem comes together to get deals done,” said Sarah Rowlands, marketing director.
“The Innovation Showcase puts promising start ups directly in front of the people who can take them to the next level.”
The showcase sits at the heart of a three-day programme spanning digital health, therapeutics, diagnostics, and consumer health.
Previous attendees have included representatives from Mayo Clinic, CVS Health, Eli Lilly, Brigham and Women’s Hospital, Alumni Ventures, Muse Capital, and Maverick Ventures, among hundreds of others.
Applications are open now. Start-ups can submit at
www.whisusa.com/attend/start-ups
About WHIS
Now in its eighth year, the Women’s Health Innovation Summit is the largest global gathering of senior leaders shaping the future of women’s health.
Organised by Kisaco Research, WHIS unites providers, health plans, employers, regulators, pharma, investors, and innovators to increase deal flow, expand reimbursement, improve access, and deliver better health outcomes for women at every stage of life.
WHIS 2026 takes place October 13–15 at Encore Boston Harbor, Everett, MA.
Learn more at www.whisusa.com
Five women-led startups will compete for a share of a £30,000 prize fund in Imperial’s WE Innovate final on Monday 15 June 2026.
The finalists are building businesses to tackle challenges in areas including vaccine technology, epilepsy care and the destruction of “forever chemicals”.
The WE Innovate programme, run by Imperial Enterprise Lab, is a targeted pre-accelerator open to teams led by students, recent alumni and early career researchers who identify as women.
The programme supports 25 women-led teams through six months of masterclasses, business coaching, one-to-one expert support and peer mentoring.
The top five teams will compete to win a share of the £30,000 prize fund at the WE Innovate Grand Final Showcase at Imperial on Monday 15 June 2026 from 18:00 to 21:00.
Tickets are free and available on a first-come, first-served basis.
This year’s final also marks the second year of WE Innovate National, a growing UK-wide programme that has expanded the WE Innovate model built at Imperial to other parts of the country.
Alongside Imperial, Queen’s University Belfast, Swansea University and Loughborough University are each hosting their own grand final showcases on their campuses.
The four showcases are collectively contributing to a shared national ecosystem focused on supporting women-led innovation.
WE Innovate National is set to expand to seven universities next year, supporting 175 women-led startup teams across the UK.
AlphaVectors Biotech is developing a lipid nanoparticle platform to enhance the stability of RNA vaccines at room temperatures.
Lipid nanoparticles are tiny fat-based particles used to deliver genetic medicines into the body. RNA vaccines use genetic instructions to help the immune system recognise a disease target.
Current RNA-based therapeutics rely on lipid nanoparticles that need storage at between -20°C and -80°C and high dosing. This increases distribution costs and leads to significant wastage, limiting scalability, deployment and accessibility in lower-resource markets.
AlphaVectors Biotech says its technology can lower the need for temperature-controlled supply chains, reduce costs and improve the scalability of RNA vaccines for wider deployment.
The startup is led by Dr Apanpreet Kaur, an Imperial alumnus with a PhD in chemical engineering.
Epile-X, by NeuraVance Labs, is working on a platform that could provide continuous, real-world brain monitoring for people with epilepsy.
More than 630,000 people in the UK live with epilepsy, according to the charity Epilepsy Action.
Epilepsy is a neurological condition that can cause recurring seizures. EEG, or electroencephalography, is a test that records electrical activity in the brain.
Current diagnosis relies on EEG recordings in clinical settings and patient-reported diaries, which may miss seizures that happen during daily life.
The startup says its technology combines a wearable EEG with AI-driven analysis to capture daily brain activity and support improved diagnosis and more personalised treatment decisions.
Epile-X is led by Ester D’Alterio, an innovation, entrepreneurship and management MSc graduate from Imperial.
FluoroCycle is developing technology for low-energy chemical destruction of PFAS, breaking down “forever chemicals” at 10 times lower temperatures than current incineration methods.
PFAS are synthetic chemicals found in air, water and soil. Some studies have linked exposure to them to health risks including thyroid disease, reproductive illness and cancer.
The startup aims to make PFAS destruction more affordable by providing its technology as an onsite engineered unit, allowing customers to save on energy and transport costs while cutting their carbon footprint.
FluoroCycle is led by Amanda Fogh, a research associate in Imperial’s department of chemistry.
Waypoint is building a video game controller for visually impaired players to hear and feel popular games, including Super Mario and Minecraft.
At least 2.2 billion people globally have some form of vision impairment, according to the World Health Organisation, while estimates show around 43 million people have complete blindness.
Waypoint says only 0.001 per cent of video games are fully playable for blind gamers.
The startup’s technology uses computer vision and AI to read the game screen and translate key information into sound, vibration and touch for a fully immersive experience.
The founders say it is the first game controller designed to make video games fully playable for blind players.
Waypoint is led by Bana Quronfuleh, an innovation design engineering MSc student at Imperial.
Snitch is developing an accountability-based app that allows friends to cut down their screen time together.
UK adults spend an average of 4.5 hours a day online on personal smartphones, tablets and computers, according to Ofcom’s Online Nation 2025 report.
Young adults spend more than six hours online on average. Some research suggests excessive screen use may have a negative impact on mental and physical health.
The app allows users to join accountability groups and set shared limits across their most used apps.
When one person scrolls, the group’s combined timer counts down. The founders say this helps build awareness, encourage reflection and create small behavioural shifts by making screen use a shared responsibility.
Snitch is led by Asha Bakhai, a design engineering MEng graduate from Imperial.
Indian pharmaceutical giant Sun Pharma has agreed to buy Organon for US$11.75bn in a deal aimed at expanding its women’s health and biosimilars business.
Organon, which was spun out of Merck in 2021, has built a portfolio of more than 70 women’s health and general medicines products, including biosimilars, sold in the US and about 140 other countries.
The acquisition would give Sun Pharma a broader presence in biosimilars, which are medicines designed to be highly similar to existing biological drugs, and strengthen its position in women’s health.
Dilip Shanghvi, executive chairman of Sun Pharma, said: “Organon’s portfolio, capabilities, and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.”
The companies said the combined business would generate annual revenue of US$12.4bn, operate across 150 countries and rank among the top three companies globally in women’s health.
They also said it would become the seventh largest biosimilar player.
Sun Pharma said the deal would help grow its innovative medicines business and expand its biosimilars offering.
It added that the combined company would have 18 large markets each generating more than US$100m in revenue.
Organon’s largest markets include the US, Brazil, Canada, China and countries in the European Union. The company also has six manufacturing facilities across the EU and emerging markets.
The deal follows market speculation that began on 10 April, when Indian media reported that Sun Pharma had submitted an all-cash offer for Organon.
A later report said the offer had been revised to US$13bn. Sun Pharma shares rose about 7 per cent on India’s National Stock Exchange after the announcement.
Sun Pharma said it would acquire all of Organon’s issued and outstanding shares in cash, using a combination of available cash and committed bank financing. It also estimated synergies of about US$350m within two to four years of completion.
The company said the acquisition would strengthen its cash generation, with EBITDA and cash flow set to nearly double, supporting efforts to reduce the net debt to EBITDA ratio of 2.3 times resulting from the deal. EBITDA is a measure of operating performance before certain costs are deducted.
Organon reported revenue of US$6.2bn last year and adjusted EBITDA of US$1.9bn. It also reported debt of US$8.64bn, down from US$9.5bn when it separated from Merck, and a cash balance of US$574m.
In November, Organon announced plans to sell its JADA System, designed to control and treat abnormal postpartum uterine bleeding or haemorrhage, to Laborie Medical Technologies for up to US$465m. Net proceeds from the sale will contribute to Organon’s cash balance as of 31 March 2026.
Organon will merge with a subsidiary of Sun Pharma, with Organon surviving the merger. The boards of both companies have approved the transaction.
Carrie Cox, executive chair of Organon, said: “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders.”
The transaction is expected to close in early 2027, subject to regulatory approvals and Organon stockholder approval.
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Mental health4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Diagnosis2 weeks agoNHS urged to update website following renaming of PCOS
News6 days agoThree menopause innovators shortlisted for Femtech World Award